Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets
Women’s wellness initiative promoted preventive healthcare, fitness, and self-care awareness across the Mira Bhayandar community
Investment will support LifeSigns’ global expansion across Southeast Asia and GCC markets
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
CoMira Diagnostics will manufacture PCR diagnostic instruments and medical consumables in Sudair Industrial City
This is an exciting and meaningful milestone for GRIN Therapeutics
Subscribe To Our Newsletter & Stay Updated
